.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, individuals with metastatic gastrointestinal lumps that got biomarker-matched treatments based on flowing lump DNA profiling presented a higher professional perk than those getting unmatched therapy.